Loading...
One might think that developing drugs that target glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors has run its course, but that's not the case. Researchers examined several variations on currently available drugs in recently published, industry-sponsored, randomized trials. Some examples follow:
Maridebart cafraglutide is an injected long-acting GLP-1 agonist and GIP antagonist; an advantage is that it can be given monthly, rather than daily or weekly. In a 1-year trial that involved patients with obesity, the highest dose reduced body weight by an average of 16% among patients with obesity (but not diabetes). Among those with diabetes, mean decrease in weight was 12%, and mean decrease in glyc…
